Newron Pharmaceut. Stock
€7.33
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Newron Pharmaceut.
sharewise wants to provide you with the best news and tools for Newron Pharmaceut., so we directly link to the best financial data sources.
Financials
News
EQS-News: Newron announces approval for pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)
EQS-News: Newron presents 2024 financial results and provides 2025 outlook
EQS-News: Newron proposes renowned biopharma company founder and entrepreneur Dr. Chris Martin for election as Independent Chairman
EQS-News: Newron and Myung In Pharm announce license agreement for evenamide in South Korea
Newron Announces Approval for Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-resistant Schizophrenia (TRS)
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
Newron Presents 2024 Financial Results and Provides 2025 Outlook
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
Newron Pharmaceuticals to Participate in a Fireside Chat at the 37th Annual ROTH Conference
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for diseases of the central and peripheral nervous
Newron and Myung In Pharm Announce License Agreement for evenamide in South Korea
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for diseases of the central and peripheral nervous